Thursday, October 11, 2018 9:46:32 AM
BY GLOBENEWSWIRE — 8 MINUTES AGO
BATON ROUGE, La., Oct. 11, 2018 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the development of a proprietary immunotherapy cancer vaccine technology and targeted cancer therapies, is pleased to announce that the protocol for the planned Phase 2 clinical trial of ProscaVax for advanced prostate cancer to be hosted at Urology Clinics of North Texas (UCNT) has been submitted to the U.S. Food and Drug Administration for approval to initiate the study. We expect the FDA and IRB process to move quickly and have the first patient injected before the first of December.
The trial is designed to build upon a successfully completed Phase 1a trial of ProscaVax in patients with advanced prostate cancer that have failed previous therapy with documented rising prostate specific antigen (PSA). In the Phase 1a trial, ProscaVax, the Company’s lead immunotherapy platform candidate consisting of a combination of prostate cancer associated PSA with the biological adjuvants interleukin-2 (IL-2) and granulocyte-macrophage colony-stimulating factor (GM-CSF), was shown to be safe and well tolerated.
At 19 weeks post-therapy, 80 percent of patients (n=20) in the Phase 1a trial demonstrated stable disease/no prostate cancer progression. Of those 16 patients, 12 completed additional follow-up examinations at 43 weeks post-therapy. Overall survival was 100% for all 20 patients and 12 of the 17 evaluable patients (70.6%) continued to live with stable/progression-free disease.
The latest study is structured to expeditiously add to the body of clinical evidence supporting the safety and efficacy of ProscaVax by using an independent Institutional Review Board and accessing for enrollment the large population of prostate cancer patients being treated at UCNT. UCNT is a premier urology group with ten centers in North Texas and a team that includes 12 physicians honored with inclusion in the peer-selected “The Best Doctors in America” list.
“We are thrilled to be working with the esteemed prostate cancer experts at UCNT and to have completed all necessary negotiations and protocol finalizations to move towards a second clinical trial of ProscaVax in late-stage patients. We believe that ProscaVax will again be able to deliver a meaningful therapeutic benefit to these patients with advanced disease that currently are presented with almost no safe and effective options,” commented Dr. Jonathan Head, Chief Executive Officer at OncBioMune. “Combined with the initiation of the world’s first ever study of a vaccine in early-stage prostate cancer patients in ‘active surveillance’ at a teaching hospital of Harvard University, we are steadily building our position as a leader in immunotherapy with a novel approach to prostate cancer. As we grow this footprint, we believe that there will be an increase in our market valuation followed by potential partnering opportunities.”
About Prostate Cancer
According to the American Cancer Society (ACS), prostate cancer is the most common type of cancer in men other than skin cancer, with about 1 in 9 men diagnosed during their lifetime. ACS estimates that about 164,690 new cases of prostate cancer will be diagnosed during 2018 and approximately 29,430 men will die from the disease this year. Prostate cancer is the second leading cause of cancer death in men, trailing only lung cancer. Approximately 2.9 million men are living with prostate cancer today. The average age of diagnosis is 66, with the disease considered rare in men under the age of 40.
Sign up for OncBioMune email alerts at: http://oncbiomune.com/email-alerts/.
About OncBioMune Pharmaceuticals, Inc. (OBMP)
OncBioMune Pharmaceuticals (OBMP) is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, based on their proprietary vaccine technology designed to stimulate the immune system to attack tumor cells without damaging healthy tissue. Our lead pipeline product, ProscaVax™, has successfully completed enrollment and vaccination of 20 prostate cancer patients and is collecting long-term follow-up results for the 1a portion of their Phase 1a/1b clinical trial. Due to the impressive results and proven safety profile of ProscaVax™, OncBioMune is forgoing the 1b portion of the trial to advance ProscaVax™ into Phase 2 studies. A Phase 2 trial is scheduled to commence at Beth Israel Deaconess Medical Center a Harvard University teaching hospital evaluating ProscaVax as a front-line therapy in prostate cancer patients in the “active surveillance” category, representing the first mid-stage trial of an immunotherapeutic vaccine in this patient population. OncBioMune also has a portfolio of targeted therapies, some of which are biosimilars and generics to blockbuster drugs. OncBioMune is headquartered in Baton Rouge, LA.
Recent THER News
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 09:29:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/20/2024 08:35:09 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 02/15/2024 10:28:54 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 02/15/2024 08:00:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/03/2024 01:10:18 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/26/2024 11:28:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/26/2024 11:17:03 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 12/29/2023 04:26:15 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 12/19/2023 09:51:04 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/21/2023 08:08:50 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/15/2023 08:46:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/29/2023 08:01:16 PM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM